An anticancer drug developed by Sichuan Biokin Pharmaceutical took centre stage in a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) Congress in Madrid last week.
Researchers said the drug, iza-bren, showed a significant advantage over platinum-based chemotherapy in a phase 3 randomised, double-blind clinical trial conducted at 73 hospitals in China and involving 432 patients with advanced lung cancer.
The median progression-free survival (PFS) – the length of...
Chinese drug iza-bren doubles lung cancer survival window in phase 3 trial
Global - Asia
Archived
•
November 3, 2026
•
Source: South China Morning Post | https://www.scmp.com/rss/91/feed - Read Original
Discussion (0)
Please log in to post a comment.
No comments yet. Be the first to share your thoughts!



